Table 3.
Molecular markers of drug resistance in the two study sites
| Faladje | Bougoula-Hameau | |||||
|---|---|---|---|---|---|---|
| Genes | Antimalarial | Amino Acid Positions | Wild Type Haplotype | Mutants %(N) | p | |
| PfK13 | artemisinin | any mutation seen in BTB/POZ | 0 (120) | 1 (100) | 0.2 | |
| Pfdhfr-Triple-mutation | pyrimethamine | 51,59,108 | NCS | 83.7(140) | 79.6(166) | 0.3614 |
| Pfdhfr-Pfdhps quadruple mutation | Sulfadoxine-pyrimethamine | 51,59,108, 480 | NCS-A | 52.6(140) | 52(166) | 0.9 |
| Pfdhfr-Pfdhps quintuple mutation | Sulfadoxine-pyrimethamine | 51,59,108, 480, 540 | NCS-AK | 0 (140) | 0.6 (166) | 0.3 |
| Pfmdr1 | chloroquine, amodiaquine, lumefantrine, mefloquine | 86 | N | 40(118) | 38.8(163) | 0.8 |
| Pfcrt | chloroquine | 76 | K | 30(110) | 23.7(71) | 0.3 |
| PGB (ART-R genetic background), arps10, ferredoxin, Pfcrt, Pfmdr2 | artemisinin | arps10-127; ferredoxin-193; Pfcrt-326, 356; Pfmdr2-484 | VDNIT | 32.6(126) | 29.6(151) | 0.5 |